TEL

Medical technology back on track

Retrieved on: 
Wednesday, March 13, 2024

The broad healthcare sector and the medical technology sector, buoyed by resurgent investor interest, delivered even better returns.

Key Points: 
  • The broad healthcare sector and the medical technology sector, buoyed by resurgent investor interest, delivered even better returns.
  • “We also anticipate a big boost in growth from the increasing use of artificial intelligence in the medical technology and healthcare services industries,” Stefan Blum adds.
  • These were generally characterized by strong growth momentum in surgical procedures and an optimistic outlook for the 2024 fiscal year,” Marcel Fritsch comments.
  • Elevance, which is focused on employer-sponsored health insurance plans, reported better-than-expected profits thanks to a drop in medical costs and an increase in management’s earnings guidance for 2024.

The National Anti-Corruption Commission Thailand Alerts Investors to Risks of Gratuity Offerings as Potential Bribery

Retrieved on: 
Wednesday, March 13, 2024

The NACC's Secretary-General, Mr. Niwatchai Kasemmongkol, emphasized that the regulatory framework established in 2020 includes criminal penalties for such offenses.

Key Points: 
  • The NACC's Secretary-General, Mr. Niwatchai Kasemmongkol, emphasized that the regulatory framework established in 2020 includes criminal penalties for such offenses.
  • The code aims to prevent the masking of bribes as gratuities, a practice that is identified as a seedbed for bribery and corruption, posing significant hurdles to national development and contravening legal standards.
  • This warning aligns with the stance of Transparency International (TI), which categorizes bribery as a form of corruption that must be eradicated.
  • The National Anti-Corruption Commission (NACC) is a constitutional independent organization supervised by nine commissioners selected from various professions.

SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder

Retrieved on: 
Friday, March 8, 2024

“Scientific innovation cannot forge ahead without patients that are willing to work with the scientific community by participating in clinical trials.

Key Points: 
  • “Scientific innovation cannot forge ahead without patients that are willing to work with the scientific community by participating in clinical trials.
  • The enrollment of our first patient means that we are moving towards a new frontier in the treatment of ASD,” said Oz Adler, SciSparc’s Chief Executive Officer.
  • “We are pleased to enroll the first patient in the trial, which will further our understanding of the potential role of SCI-210 in the treatment of ASD symptoms."
  • The Company's goal is to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals.

SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe

Retrieved on: 
Thursday, March 7, 2024

TEL AVIV, Israel, March 07, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that the process of granting and validation for its core-technology patent has been completed in certain European countries. This patent covers combinations of cannabinoids and n-acylethanolamines (the “Patent”). The Patent aligns seamlessly with the Company's proprietary technology designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.

Key Points: 
  • This patent covers combinations of cannabinoids and n-acylethanolamines (the “Patent”).
  • The Patent aligns seamlessly with the Company's proprietary technology designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.
  • The Patent was granted and validated in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Liechtenstein and the United Kingdom.
  • This grant adds to the patent portfolio of the Company, thereby supporting the innovation of SciSparc’s technologies.

SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology

Retrieved on: 
Wednesday, March 6, 2024

The Patent has been granted by the Canadian Intellectual Property Office, the government agency in Canada that administers intellectual property rights and legislation for patents.

Key Points: 
  • The Patent has been granted by the Canadian Intellectual Property Office, the government agency in Canada that administers intellectual property rights and legislation for patents.
  • "With the Canadian patent approval for our opioid reduction technology, SciSparc continues to build on global recognition of its innovations and breakthrough technologies.
  • We are all aware of how effective opiates are in relieving pain, but also for their addictive influence.
  • Our technology represents hope for safer and more effective pain management strategies worldwide," said SciSparc’s Chief Executive Officer, Oz Adler.

Tabnine to Showcase AI-Driven Software Development at Nvidia GTC 2024

Retrieved on: 
Wednesday, March 6, 2024

When: Tuesday, March 19 from 4:00-4:25 p.m. PDT

Key Points: 
  • When: Tuesday, March 19 from 4:00-4:25 p.m. PDT
    AI-driven software development is poised to transform the entire software development life cycle (SDLC).
  • Learn the challenges and solutions for AI-driven software development, including:
    How does the SDLC change when autonomous agents can handle some tasks?
  • You'll also learn practical AI-assisted software development techniques based on the experience of Tabnine, a company that serves millions of users with AI-powered code completion.
  • Tabnine will be onsite at Nvidia GTC 2024 at booth #G101.

IONIX Enhances ASM Platform with Automated Exposure Validation for Continuous Exploitability Testing

Retrieved on: 
Wednesday, March 6, 2024

TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- IONIX today announced a significant extension to its industry-leading Attack Surface Management (ASM) platform, Automated Exposure Validation.

Key Points: 
  • TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- IONIX today announced a significant extension to its industry-leading Attack Surface Management (ASM) platform, Automated Exposure Validation.
  • Customers of IONIX can now benefit from Exposure Validation capabilities for continuous exploitability testing on production environments without risk of disruption.
  • In contrast, IONIX Exposure Validation employs non-intrusive attack simulations, ensuring continuous validation of the entire attack surface without risk of disruption to production systems.
  • “With Automated Exposure Validation and the IONIX ASM platform, enterprises move from drowning in numerous theoretical risks to fixing actual validated exposures.

REE Announces Closing of Public Offering of Ordinary Shares

Retrieved on: 
Wednesday, March 6, 2024

TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE), an automotive technology company and provider of full by-wire electric trucks and platforms, today announced the closing of its previously announced underwritten public offering of 2,300,000 Class A ordinary shares (the “ordinary shares”), which includes the full exercise of the underwriter’s overallotment option. Each ordinary share was sold at a public offering price of $6.50 per share.

Key Points: 
  • -   Multiple investors participated in the round, led by M&G, REE’s largest investor
    TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE), an automotive technology company and provider of full by-wire electric trucks and platforms, today announced the closing of its previously announced underwritten public offering of 2,300,000 Class A ordinary shares (the “ordinary shares”), which includes the full exercise of the underwriter’s overallotment option.
  • Each ordinary share was sold at a public offering price of $6.50 per share.
  • The gross proceeds to REE from the offering are approximately $14.95 million, before deducting the placement agent’s fees and other offering expenses payable by REE.
  • REE intends to use the net proceeds from the offering primarily for working capital and general corporate purposes, including continued product development and commercialization.

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 6, 2024

TEL AVIV, Israel and MIAMI, March 06, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • Fourth Quarter 2023 and Recent Developments:
    Generated record CGuard revenue in the fourth quarter 2023 of $1.76 million, a 71.6% increase over the fourth quarter of 2022.
  • Sold 3,107 CGuard EPS stent systems in the fourth quarter of 2023, as compared to 1,781 in the fourth quarter of 2022, an increase of 74.5%.
  • Financial Results for the Fourth Quarter Ended December 31, 2023
    For the fourth quarter of 2023, total revenue increased 71.6%, to $1,761,000, from $1,026,000 during the fourth quarter of 2022.
  • Total financial income for the fourth quarter of 2023 was $468,000, an increase of $349,000 or 293% compared to $119,000 for the third quarter of 2022.

REE Automotive selected by Airbus UpNext

Retrieved on: 
Tuesday, March 5, 2024

TEL AVIV, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE) (“REE” or the “Company”) has been selected by Airbus UpNext, wholly-owned innovation subsidiary of Airbus SE (stock exchange symbol: EADSY), to provide technological know-how based upon its REEcorner® and full-by-wire control systems.

Key Points: 
  • TEL AVIV, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (Nasdaq: REE) (“REE” or the “Company”) has been selected by Airbus UpNext, wholly-owned innovation subsidiary of Airbus SE (stock exchange symbol: EADSY), to provide technological know-how based upon its REEcorner® and full-by-wire control systems.
  • “Our fully-by-wire technology was carefully selected by Airbus UpNext to support their need in a research & technology demonstrator,” said Tali Miller, Chief Business Officer of REE.
  • “This contract is a recognition for our fully-by-wire technology.”
    To learn more about REE’s patented technology and unique value proposition that positions the company to break new ground in e-mobility, visit www.ree.auto .